Christina L. Zuch de Zafra

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

Christina L. Zuch de Zafra, Flordeliza Fajardo, Wendy Zhong et al. · Clinical Cancer Research · 2019 · 127 citations

Life Sciences, Immunology, Oncology +17

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

Karin Staflin, Christina L. Zuch de Zafra, Leah Schutt et al. · JCI Insight · 2020 · 99 citations · Full text

Medicine, Oncology, Pharmacology +17

Host cell proteins in biotechnology‐derived products: A risk assessment framework

Christina L. Zuch de Zafra, Valerie Quarmby, Kathleen Francissen et al. · Biotechnology and Bioengineering · 2015 · 69 citations

Engineering, Bioengineering, Biotechnology +17

Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics

Christina L. Zuch de Zafra, Vito G. Sasseville, Steven S. Matsumoto et al. · Regulatory Toxicology and Pharmacology · 2017 · 39 citations

Medicine, Immunology, Ophthalmology +12

Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine

Michelle Z. Dion, Danielle L. Leiske, Vikas Sharma et al. · Pharmaceutical Research · 2018 · 39 citations

Pharmacy, Biochemistry, Pharmacology +11